-

Thermo Fisher Scientific and Structura Biotechnology Collaborate to Offer a Solution for Real-Time Cryo-EM Data Analysis

New Embedded CryoSPARC Live software to be made available by Structura and Thermo Fisher and designed to integrate with Thermo Fisher technology

HILLSBORO, Ore.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, and Structura Biotechnology Inc., a leading provider of cryo-EM data analysis software, today announced a collaboration to make available a new single particle analysis software solution, a version of Structura’s CryoSPARC Live, that is designed to integrate with Thermo Fisher’s Smart EPU software and cryo-transmission electron microscope (cryo-TEM) technology. The new solution, Embedded CryoSPARC Live, will be offered as a subscription.

Embedded CryoSPARC Live will enable cryo-electron microscopy (cryo-EM) users of all experience levels to obtain high-quality data while reducing the time it takes to transform raw data into high-quality 3D protein structures from days to hours.

Embedded CryoSPARC Live will offer real-time cryo-EM data analysis, including pre-processing (motion correction and CTF estimation), particle picking and extraction, streaming 2D classification, ab-initio 3D reconstruction, and streaming 3D refinement. This workflow will enable users to make decisions to optimize data acquisition and can be used as an input for Smart EPU plugins, which automatically adjust EPU data acquisition parameters in real-time.

“We’re thrilled to make this announcement with Structura Biotechnology as we work together to make cryo-EM more accessible, productive and easy to use,” said Trisha Rice, vice president and general manager of life sciences at Thermo Fisher Scientific. “This solution represents a major step forward in our plans to deliver a fully automated and intelligent cryo-EM imaging platform.”

“We’re excited to collaborate with Thermo Fisher Scientific and deliver a powerful solution that will help users in research and commercial settings move toward a more optimized and high-throughput cryo-EM workflow,” said Ali Punjani, CEO at Structura Biotechnology.

Embedded CryoSPARC Live will soon be available as an add-on for Smart EPU users and can be configured to connect to Thermo Fisher’s entire cryo-TEM portfolio, including the Thermo Scientific Tundra, Glacios and Krios Cryo-TEMs.

To learn more, visit our Embedded CryoSPARC Live webpage.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Brianna Radicioni
Thermo Fisher Scientific
+1 617-390-3924
brianna.radicioni@thermofisher.com

THERMO FISHER SCIENTIFIC

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media:
Brianna Radicioni
Thermo Fisher Scientific
+1 617-390-3924
brianna.radicioni@thermofisher.com

Social Media Profiles
More News From THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers’ Manufacturing

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will invest an additional $2 billion in the United States over the next four years, strengthening American innovation, manufacturing and economic competitiveness across the life sciences sector. As one of the largest manufacturers of medicines in the world, Thermo Fisher enables biopharma companies to develop and produce their medicines in America. These additional investments to the...

Thermo Fisher Scientific Reports First Quarter 2025 Results

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025. First Quarter Highlights First quarter revenue was $10.36 billion. First quarter GAAP diluted earnings per share (EPS) grew 15% to $3.98. First quarter adjusted EPS grew 1% to $5.15. Delivered very strong financial performance in the quarter, demonstrating the strength of our trusted partner status and t...

Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center in Greater San Diego to Help Accelerate Cell Therapy Development

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the grand opening of its Advanced Therapies Collaboration Center (ATxCC) in Carlsbad, Calif. This advanced facility is designed to accelerate the development and commercialization of cell therapies, specifically by supporting biotech, biopharma and translational customers developing cell-based immunotherapies. Through this new center, cell therapy developers can leverage Thermo...
Back to Newsroom